Bayer announced that the U.S. Food and Drug Administration (FDA) approved AMBELVIST® (gadoquatrane), a new, intravenous macrocyclic gadolinium (Gd)-based contrast agent (mGBCA) indicated for...

The EVERY Company ("EVERY"), a leader in highly functional egg proteins produced via precision fermentation, announced a significant manufacturing expansion with its strategic partner, Huvepharma, a...

Incyte announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting...

AbbVie announced new Phase 3 data on a fixed-duration venetoclax-based combination. Final results from the Phase 3 CLL14 trial in previously untreated chronic lymphocytic leukemia (CLL), which was...

ELASTEN®, Germany's 1 liquid collagen supplement and a global leader in clinically studied ingestible skincare, announced a year-long partnership with renowned board-certified dermatologist, media...

NurtureBio, a maternal and child wellness company focused on science-backed solutions for infant gut health, announced a collaboration with Lallemand Health Solutions, the company's key partner involved...

Kyowa Hakko, a global leader in health ingredient innovation and manufacturer of branded ingredient Setria® Glutathione, announced that a supplement featuring Setria has been approved for sale in...

Roquette, a global leader in plant-based ingredients and pharmaceutical excipients, will showcase its comprehensive portfolio of innovative drug delivery solutions Under the theme “One Roquette for...

X-Therma Inc., a pioneering biotechnology company focused on revolutionizing regenerative medicine through its innovative biopreservation platform, announced the commercial launch of its XT-NoVo® and...

Johnson & Johnson is presenting the first comprehensive results from the Phase 2/3 ENERGY study showing that IMAAVY® (nipocalimab-aahu) produced a statistically significant durable hemoglobin (Hgb)...

VERTANICAL announced that Exilby® (VER-01) has received marketing authorization in Germany for the treatment of chronic low back pain with a radicular (neuropathic)...

Alpha Cognition Inc. a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, announced the top-line results from its BEACON real-world study...